NCT06239480Phase 3Active not recruiting

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Study sponsor: Palvella Therapeutics, Inc. · PVLA

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-01-14Actual
Enrollment · participants51Actual
Source updated2026-03-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 40 participants (planned). After: 51 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jan 2026. After: 14 Jan 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview